San Diego, CA, United States of America

Robert Mansfield

This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: Eli Lilly and Company. Active years: 2025-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Robert Mansfield

Introduction

Robert Mansfield is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations that target the farnesoid X receptor. His work is crucial in addressing various medical conditions associated with this receptor's activity.

Latest Patents

Mansfield holds a patent for "Formulations of a farnesoid X receptor agonist." This patent describes pharmaceutical formulations of a specific farnesoid X receptor agonist, which includes a complex chemical structure aimed at treating conditions related to farnesoid X receptor activity. He has 1 patent to his name, showcasing his innovative approach to pharmaceutical development.

Career Highlights

Robert Mansfield is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His role involves research and development, where he applies his expertise to create effective therapeutic solutions. His work at Eli Lilly has positioned him as a key player in the pharmaceutical industry.

Collaborations

Mansfield collaborates with various professionals in his field, including his coworker Nicholas D. Smith. Together, they work on advancing pharmaceutical formulations and exploring new therapeutic avenues.

Conclusion

Robert Mansfield's contributions to pharmaceutical innovations highlight his dedication to improving healthcare through targeted therapies. His work continues to influence the development of treatments for conditions associated with farnesoid X receptor activity.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…